新发晚期急性GVHD的发病率、临床表现、危险因素、结局和生物标志物
在24个MAGIC中心3542例首次异基因造血细胞移植的成人受者中,需系统治疗的经典急性GVHD累积发生率为35.2%,另有5.7%的患者因晚期急性GVHD需要治疗。晚期急性GVHD起病时临床和MAGIC生物标志物评分均比经典急性GVHD更严重,第28天总缓解率更低,但长期非复发死亡率和总生存无差异。高龄、女供男受者和减低强度预处理与晚期急性GVHD发生相关,移植后环磷酰胺为基础的GVHD预防主要通过改变GVHD发生时机起保护作用。
要点
- 经典急性GVHD需系统治疗的累积发生率为35.2%,另有5.7%因晚期急性GVHD需治疗。
- 晚期急性GVHD起病时临床和生物标志物评分更严重,第28天总缓解率更低。
- 高龄、女供男受者和减低强度预处理与晚期急性GVHD发生相关。
核心结论
- 晚期急性GVHD起病时比经典急性GVHD更严重且第28天总缓解率更低,但长期非复发死亡率和总生存无差异。
- 作者认为,基于起病时临床表现采用相似治疗策略(包括临床试验入组资格)是合适的,但该发现并非定论。
研究设计与样本
- 研究评估了2014年1月至2021年8月期间在24个Mount Sinai急性GVHD国际联盟(MAGIC)中心连续接受首次异基因造血细胞移植(HCT)的3542例成人受者。
- 晚期急性GVHD定义为异基因HCT后100天以后出现、无慢性GVHD表现的新发急性GVHD。
主要发现
- 需系统治疗的经典急性GVHD累积发生率为35.2%,另有5.7%的患者因晚期急性GVHD需要治疗。
- 晚期急性GVHD起病时基于临床和MAGIC算法概率生物标志物参数均比经典急性GVHD更严重,第28天总缓解率更低。
- 治疗时临床和生物标志物分级分别对经典和晚期急性GVHD患者的非复发死亡率(NRM)风险进行分层,但长期NRM和总生存在经典与晚期急性GVHD患者之间无差异。
- 高龄、女供男受者和使用减低强度预处理与晚期急性GVHD发生相关。
- 使用移植后环磷酰胺为基础的GVHD预防具有保护作用,主要因为GVHD发生时机改变。
临床怎么用
- 作者认为,由于总体结局相当,基于起病时临床表现采用相似治疗策略(包括临床试验入组资格)是合适的,但该发现并非定论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Late acute graft-versus-host disease (GVHD) is defined as de novo acute GVHD presenting beyond 100 days after allogeneic hematopoietic cell transplantation (HCT) without manifestations of chronic GVHD. Data are limited regarding its characteristics, clinical course, and risk factors because of underrecognition and changes in classification. We evaluated 3542 consecutive adult recipients of first HCTs at 24 Mount Sinai Acute GVHD International Consortium (MAGIC) centers between January 2014 and August 2021 to better describe the clinical evolution and outcomes of late acute GVHD. The cumulative incidence of classic acute GVHD that required systemic treatment was 35.2%, and an additional 5.7% of patients required treatment for late acute GVHD. At the onset of symptoms, late acute GVHD was more severe than classic acute GVHD based on both clinical and MAGIC algorithm probability biomarker parameters and showed a lower overall response rate on day 28. Both clinical and biomarker grading at the time of treatment stratified the risk of nonrelapse mortality (NRM) in patients with classic and late acute GVHD, respectively, but long-term NRM and overall survival did not differ between patients with classic and late acute GVHD. Advanced age, female-to-male sex mismatch, and the use of reduced intensity conditioning were associated with the development of late acute GVHD, whereas the use of posttransplant cyclophosphamide-based GVHD prevention was protective mainly because of shifts in GVHD timing. Because overall outcomes were comparable, our findings, although not definitive, suggest that similar treatment strategies, including eligibility for clinical trials, based solely on clinical presentation at onset are appropriate.
引用
- Akahoshi Y, Spyrou N, Hogan WJ, et al. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Adv. 2023. PMID: 37315175. doi:10.1182/bloodadvances.2023009885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。